Fulltext

The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

Gratwohl, Alois ; Baldomero, Helen ; Passweg, Jakob

In: Annals of Hematology, 2015, vol. 94, p. 177-186

Ajouter à la liste personnelle
    Titre
    • The role of hematopoietic stem cell transplantation in chronic myeloid leukemia
    Auteur
    • Gratwohl, Alois. Hematology, University Hospital, Dittingerstrasse 4, 4053, Basel, Switzerland
    • Baldomero, Helen. Hematology, University Hospital, Dittingerstrasse 4, 4053, Basel, Switzerland
    • Passweg, Jakob. Hematology, University Hospital, Dittingerstrasse 4, 4053, Basel, Switzerland
    Type de document
    • Postprint
    Identifiant OAI-PMH
    • oai:doc.rero.ch:332469
    Summary
    Allogeneic hematopoietic stem cell transplantation (HSCT) is currently recommended as 2nd or 3rd line therapy for patients with chronic myeloid leukemia (CML) in first chronic phase or as salvage for patients with very advanced disease. As a consequence, numbers of HSCT in chronic phase have dropped significantly since the introduction of tyrosine kinase inhibitors (TKI), numbers of transplants in advanced disease to a lesser extent. These current recommendations consider primarily disease risk, defined as failure of TKI therapy; they might need to be adapted. We propose a more balanced appraisal of HSCT for individual patients which should include disease risk, transplant risk, and macroeconomic aspects. HSCT should be integrated into the treatment algorithms from diagnosis and be considered very early at first TKI failure for patients with high disease but low transplant risk. For patients with very advanced disease and high transplant risk in contrast, HSCT might only be recommended in a restricted research setting.